LNSR News and Press, LENSAR Inc. From 03/09/23

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2022 financial r...

LENSAR ( NASDAQ: LNSR ) expects Q4 total of ~$10.2M, up 32% Q/Q. As of December 31, 2022, LENSAR installed ten ALLY Systems and executed contracts for an additional six ALLY Systems, which are expected to be installed in H2 2023. Total revenue FY 2022 was ~$35.4M, as compared to t...

Installed ten ALLY ® Adaptive Cataract Treatment Systems in 2022 Contracts for an additional six ALLY Systems executed in December 2022; Installations expected in first half 2023 LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a glob...

LENSAR, Inc. (LNSR) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call Participants Samuel Brodovsky - B...

LENSAR press release ( NASDAQ: LNSR ): Q3 GAAP EPS of -$0.39 beats by $0.23 . Revenue of $7.75M (-6.6% Y/Y) misses by $0.15M . For further details see: LENSAR GAAP EPS of -$0.39 beats by $0.23, revenue of $7.75M misses by $0.15M

Company Launches ALLY™ Adaptive Cataract Treatment System Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021 LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2022 financial result...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptiv...

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the first commercial cases performed with the ALLY ™...

LENSAR, Inc. (LNSR) Q2 2022 Earnings Conference Call August 08, 2022, 08:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Ryan Zimmer...